RxDoctor Payments Data

Luigi di Biase, MD

Cardiovascular Disease · Bronx, NYNPI 1891045837

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $603,432 of the $977,576 with a category attached, or 61.7%. 21 manufacturers reported payments, led by Biosense Webster, Inc. at 40.6% of the total. 2025 is the largest year on record at $320,216, 3.0 times the $105,916 reported in 2019. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$977,576in general payments, 2019–2025

Across 990 payments — averaging $987.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biosense Webster, Inc.$397K
  • Medical Device Business Services, Inc.$190K
  • Biotronik Inc.$142K
  • Boston Scientific$106K
  • Medtronic$63K
  • Abbott$20K
  • plus $59K from 15 others
$1,520,670in research payments, 2019–2025

Across 2,457 payments — averaging $618.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medical Device Business Services, Inc.$401K
  • Biotronik Inc.$354K
  • Biosense Webster, Inc.$304K
  • Boston Scientific$241K
  • Medtronic$188K
  • Atricure, Inc.$32K

What the payments were for

  • Consulting fees$603,43262%
  • Speaking & faculty fees$186,81319%
  • Travel & lodging$141,99015%
  • Food & beverage$45,3285%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$977,576 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$184,386
Medicare patients
925
Services billed
3,249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban147$101,072
XareltoRivaroxaban43$31,223
Amiodarone Hcl60$1,873
Matzim LaDiltiazem Hcl11$638
Metoprolol Succinate44$288
Metoprolol Tartrate35$113
Furosemide12$6

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →